Fingerprint
Dive into the research topics where Robert R Mc Williams is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
-
Genetic Epidemiology of Young-Onset Pancreatic Cancer
Mcwilliams, R. R. (CoPI) & Mc Williams, R. R. (PI)
7/1/06 → 12/30/11
Project: Research project
-
ASO Visual Abstract: Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer-A Prospective Cohort Study
Leiting, J. L., Alva-Ruiz, R., Yonkus, J. A., Abdelrahman, A. M., Lynch, I., Carlson, D., Carr, R. M., Salomao, D. R., McWilliams, R. R., Starlinger, P. P., Thiels, C. A., Grotz, T. E., Warner, S. G., Cleary, S. P., Kendrick, M. L., Smoot, R. L., Kipp, B. R. & Truty, M. J., Jun 1 2025, In: Annals of surgical oncology. 32, 6, p. 4528-4529 2 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors
Mahadevia, H., Majeed, U., Patel, J., Ahmed, A. K., Elhariri, A., Albelal, D., Rao, N. N. M., Rachamala, H. K., Mosalem, O., Mukhopadhyay, D., Jones, J., Mahadevan, D., Borad, M. J., Ahn, D., Sonbol, M. B., Tran, N., Mahipal, A., Wee Ma, W., McWilliams, R. R. & Halfdanarson, T. R. & 4 others, , Sep 2 2025, In: JAMA Network Open. 8, 9, p. e2531373Research output: Contribution to journal › Article › peer-review
Open Access -
Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer
Steen, T. V., Espinoza, I., Duran, C., Casadevall, G., Serrano-Hervás, E., Cuyàs, E., Verdura, S., Kemble, G., Kaufmann, S. H., McWilliams, R., Osuna, S., Billadeau, D. D., Menendez, J. A. & Lupu, R., Apr 2025, In: Neoplasia (United States). 62, 101143.Research output: Contribution to journal › Article › peer-review
Open Access -
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
Kournoutas, I., Marell, P., Gile, J., Peersen, A., Shah, P., VanDommelen, K., Kamath, S. D., Gupta, G., Akce, M., Yang, J. D., Chen, P. J., Naleid, N., Mahipal, A., Peterson, N., Sahai, V., Wee Ma, W., Jin, Z., Halfdanarson, T., Fonkoua Kankeu, L. & Washburn, L. A. & 16 others, , Nov 1 2025, In: Oncologist. 30, 11, oyaf286.Research output: Contribution to journal › Article › peer-review
Open Access -
Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM
Yadav, S., Bao, R., Graham, R. P., Hu, C., Hart, S. N., Na, J., Boddicker, N., Gnanaolivu, R. D., Smadbeck, J., Ding, L., Billadeau, D. D., Mayer, A. T., Majumder, S., Morais Lyra, P. C., Lee, A. V., Monteiro, A. N., Villasboas, J. C., McWilliams, R. & Couch, F. J., Nov 1 2025, In: Clinical Cancer Research. 31, 21, p. 4463-4474 12 p.Research output: Contribution to journal › Article › peer-review
Open Access